The zyCov-D vaccine gets approval in India for emergency use

The zyCov-D vaccine gets approval in India for emergency use

The Indian drug regulator committee expert has also recommended approving Zydus Cadila's three-dose COVID-19 vaccine -ZyCoV-D- for emergency use authorization (EUA), Reuters reported citing CNBC-TV18.

The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, CNBC-TV18 said

The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorization of the vaccine ZyCoV-D on 1 July, based on an efficacy rate of 66.6% in a late-stage trial of more than 28,000 volunteers nationwide.

ZyCoV-D will become the fifth corona vaccine cleared for use in the country after locally produced Covishield, US-made Moderna, Russia's Sputnik V, and Bharat Biotech's Covaxin. Moreover, it will become the world's first DNA vaccine to get a nod in any country.

The Ahmedabad-based pharmaceutical company applied on 1 July for emergency use approval of the three-dose Covid-19 vaccine ZyCoV-D.

The company also submitted a figure estimate of a two-dose procedure of the shot. The SEC is likely to compare the data and make a decision on its go-ahead.

The zyCov D vaccine gets approval in India for emergency use 1getty image

Read More: Johnson & Johnson single dose Covid vaccine approved in India

The company has run the largest clinical trial for the COVID-19 vaccine in India in over 50 centers. The first time any COVID-19 vaccine was a trial in the adolescent population in India's 12-18 years age group. Around 1000 subjects were enrolling in the age group, and a vaccine was safe and very well tolerated. The excellent profile was similar to that seen in the adult population. Primary efficacy of 66.6% has been achieving for symptomatic RT-PCR positive cases in the interim analysis. At the same time, no moderate case of COVID-19 disease
was detected in the vaccine arm post command of the third dose, suggesting 100% efficacy for mild disease.

ZyCoV-D vaccine

ZyCoV-D is a plasmid DNA vaccine that produces the spike protein of the SARS-CoV-2. It elicits an immune response mediated by the cellular (T lymphocytes immunity) and humoral (antibody-mediated immunity) arms of the human immune system.

The vaccine has shown efficacy of 66.6% against symptomatic Covid cases and 100% for moderate disease.

It is an intradermal vaccine, applied using a 'needle-free injector.' Zydus claims the needle-free system can lead to a significant reduction in side effects.

Follow Us

Popular Post

Maharashtra SSC Board Result 2022 To Be Announced Tomorrow

Maharashtra SSC Board Result 2022 To Be Announced Tomorrow

Farhan Sayyed Jun 16, 2022 Politics

The MSBSHSE (Maharashtra State Board of Secondary and Higher Secondary Education) will announce the SSC, Class 10 exam result 2022 on Friday, June 17...